AKBA vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AKBA's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises bankruptcy risk concerns. Despite strong revenue growth (23.9% YoY) and a high gross margin (82.92%), the company operates at a net loss with negative profit and operating margins, and carries a dangerously high debt/equity ratio of 6.10. Insider selling activity totaling $0.90M over six months, including large sales by executives and the CEO, reinforces bearish sentiment. The stock trades at a premium valuation (Price/Sales: 1.66, Price/Book: 11.87) despite negative earnings and no intrinsic value support, making it vulnerable to downside pressure.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AKBA vs JNJ: Head-to-Head Comparison
This page compares Akebia Therapeutics, Inc. (AKBA) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.